Your browser doesn't support javascript.
loading
Protective Role of Nrf2 in Renal Disease.
Guerrero-Hue, Melania; Rayego-Mateos, Sandra; Vázquez-Carballo, Cristina; Palomino-Antolín, Alejandra; García-Caballero, Cristina; Opazo-Rios, Lucas; Morgado-Pascual, José Luis; Herencia, Carmen; Mas, Sebastián; Ortiz, Alberto; Rubio-Navarro, Alfonso; Egea, Javier; Villalba, José Manuel; Egido, Jesús; Moreno, Juan Antonio.
Afiliación
  • Guerrero-Hue M; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, 14004 Cordoba, Spain.
  • Rayego-Mateos S; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, 14004 Cordoba, Spain.
  • Vázquez-Carballo C; Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, Autónoma University, 28040 Madrid, Spain.
  • Palomino-Antolín A; Research Unit, Hospital Universitario Santa Cristina, IIS-Hospital Universitario de la Princesa, 28006 Madrid, Spain.
  • García-Caballero C; Departament of Pharmacology and Therapeutics, Medicine Faculty, Instituto Teófilo Hernando, Autónoma University, 28029 Madrid, Spain.
  • Opazo-Rios L; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, 14004 Cordoba, Spain.
  • Morgado-Pascual JL; Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, Autónoma University, 28040 Madrid, Spain.
  • Herencia C; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28040 Madrid, Spain.
  • Mas S; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, 14004 Cordoba, Spain.
  • Ortiz A; Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, Autónoma University, 28040 Madrid, Spain.
  • Rubio-Navarro A; Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, Autónoma University, 28040 Madrid, Spain.
  • Egea J; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28040 Madrid, Spain.
  • Villalba JM; Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, Autónoma University, 28040 Madrid, Spain.
  • Egido J; Red Nacional Investigaciones Nefrológicas (REDINREN), 28040 Madrid, Spain.
  • Moreno JA; Weill Center for Metabolic Health and Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Antioxidants (Basel) ; 10(1)2020 Dec 31.
Article en En | MEDLINE | ID: mdl-33396350
Chronic kidney disease (CKD) is one of the fastest-growing causes of death and is predicted to become by 2040 the fifth global cause of death. CKD is characterized by increased oxidative stress and chronic inflammation. However, therapies to slow or prevent CKD progression remain an unmet need. Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that plays a key role in protection against oxidative stress and regulation of the inflammatory response. Consequently, the use of compounds targeting Nrf2 has generated growing interest for nephrologists. Pre-clinical and clinical studies have demonstrated that Nrf2-inducing strategies prevent CKD progression and protect from acute kidney injury (AKI). In this article, we review current knowledge on the protective mechanisms mediated by Nrf2 against kidney injury, novel therapeutic strategies to induce Nrf2 activation, and the status of ongoing clinical trials targeting Nrf2 in renal diseases.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Antioxidants (Basel) Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Antioxidants (Basel) Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza